Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group.
Ai H, Chao NJ, Rizzieri DA, Huang X, Spitzer TR, Wang J, Guo M, Keating A, Krakow EF, Blaise D, Ma J, Wu D, Reagan J, Gergis U, Duarte RF, Chaudhary PM, Hu K, Yu C, Sun Q, Fuchs E, Cai B, Huang Y, Qiao J, Gottlieb D, Schultz KR, Liu M, Chen X, Chen W, Wang J, Zhang X, Li J, Huang H, Sun Z, Li F, Yang L, Zhang L, Li L, Liu K, Jin J, Liu Q, Liu D, Gao C, Fan C, Wei L, Zhang X, Hu L, Zhang W, Tian Y, Han W, Zhu J, Xiao Z, Zhou D, Zhang B, Jia Y, Zhang Y, Wu X, Shen X, Lu X, Zhan X, Sun X, Xiao Y, Wang J, Shi X, Zheng B, Chen J, Ding B, Wang Z, Zhou F, Zhang M, Zhang Y, Sun J, Xia B, Chen B, Ma L. Ai H, et al. Among authors: sun q, sun z, sun j, sun x. Heliyon. 2023 Mar 31;9(4):e14924. doi: 10.1016/j.heliyon.2023.e14924. eCollection 2023 Apr. Heliyon. 2023. PMID: 37089296 Free PMC article. Review.
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q. Yang S, et al. Among authors: sun xl, sun zq. Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2. Am J Hematol. 2023. PMID: 37128776 No abstract available.
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma.
Li X, Sun X, Fang B, Leng Y, Sun F, Wang Y, Wang Q, Jin J, Yang M, Xu B, Fang Z, Chen L, Chen Z, Yang Q, Zhang K, Ye Y, Geng H, Sun Z, Hao D, Huang H, Wang X, Jing H, Ma L, Pan X, Chen W, Li J. Li X, et al. Among authors: sun f, sun z, sun x. Thromb J. 2023 Oct 4;21(1):105. doi: 10.1186/s12959-023-00534-y. Thromb J. 2023. PMID: 37794471 Free PMC article.
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
Jian Y, Chang L, Shi MX, Sun Y, Chu XX, Xue H, Huang WR, Shen XL, Ma J, Jia GR, Feng YQ, Xi ZF, Zhao YH, Ma YP, Xiao J, Ma GY, Wang QM, Bao L, Dong YJ, Zhou HB, Sun CY, Su GH, Yan Y, Qimuge SY, Su LP, Sun JN, Tian WW, Sun XL, Ing HM, Gao D, Chen WM, Li J, Gao W. Jian Y, et al. Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428. Blood Adv. 2023. PMID: 37922425 Free PMC article. No abstract available.
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Liu X, Liang R, Chen C, Huang J, Zhu H, Pan L, Wang X, Li G, Liu Z, Zhang Y, Liu Z, Hu J, Liu C, Li F, Yang W, Meng L, Han Y, Lin L, Zhao Z, Tu C, Zheng C, Bai Y, Zhou Z, Chen S, Qiu H, Yang L, Sun X, Sun H, Zhou L, Liu Z, Wang D, Guo J, Pang L, Zeng Q, Suo X, Zhang W, Zheng Y, Zhang Y, Li W, Jiang Q. Zhang X, et al. Among authors: sun x, sun h. Clin Lymphoma Myeloma Leuk. 2024 Feb 15:S2152-2650(24)00067-3. doi: 10.1016/j.clml.2024.02.008. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38461040
Validation of the imatinib-therapy failure model.
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Zhang X, et al. Among authors: sun h, sun x. Leukemia. 2023 May;37(5):1166-1169. doi: 10.1038/s41375-023-01875-3. Epub 2023 Mar 27. Leukemia. 2023. PMID: 36973351 No abstract available.
Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
Zhang Y, Zhang C, Zhou J, Zhang J, Chen X, Chen J, Wang P, Sun X, Lou X, Qi W, Kang L, Yu L, Wu D, Li C. Zhang Y, et al. Among authors: sun x. Front Immunol. 2021 Feb 25;12:552429. doi: 10.3389/fimmu.2021.552429. eCollection 2021. Front Immunol. 2021. PMID: 33717057 Free PMC article.
Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.
Man X, Huang J, Sun S, Zhou D, Zhang B, Fang S, Zheng F, Li C, Wang X, Huang W, Wang L, He Q, Fu H, Zhang Y, Liu C, Dong L, Zhao X, Xu L, Sun X, Fan B, Song L, Zhou Z, Yu J, Li H. Man X, et al. Among authors: sun x. Clin Transl Med. 2024 May;14(5):e1687. doi: 10.1002/ctm2.1687. Clin Transl Med. 2024. PMID: 38738791 Clinical Trial.
40,096 results
You have reached the last available page of results. Please see the User Guide for more information.